3-Nitropropionic acid animal model and Huntington's disease

Neuroscience and Biobehavioral Reviews

Volumn 21, Issue 3, 1997, Pages 289-293

  Borlongan, Cesario V ^a,b   Koutouzis, Theodore K ^a   Sanberg, Paul R ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Uniformed Services University of the Health Sciences   (United States)

Author keywords

3 Nitropropionic acid; Huntington's disease; Locomotor activity; Mitochondrial toxin; Neurodegeneration; Striatum

Indexed keywords

3 NITROPROPIONIC ACID; 3,4 DIHYDROXYPHENYLACETIC ACID; 4 AMINOBUTYRIC ACID; ADENOSINE TRIPHOSPHATE; CHOLINE ACETYLTRANSFERASE; DOPAMINE; EXCITOTOXIN; GLUTAMATE DECARBOXYLASE; GLUTAMIC ACID; HOMOVANILLIC ACID; IBOTENIC ACID; KAINIC ACID; LACTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPEPTIDE Y; QUINOLINIC ACID; SOMATOSTATIN; SUBSTANCE P;

AEROBIC METABOLISM; ANIMAL MODEL; BASAL GANGLION; CITRIC ACID CYCLE; CORPUS STRIATUM; HUNTINGTON CHOREA; LOCOMOTION; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030999657     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(96)00027-9     Document Type: Article

References (33)

1. Albin, R. L.; Greenamyre, J. T., Alternative excitotoxic hypothesis. Neurol. 42:733-738; 1992.
2. Ankarcrona, M.; Dypbukt, J. M.; Bonfoco, E.; Zhivotovsky, B.; Orrenius, S.; Lipton, S. A.; Nicotera, P., Glutamate induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron. 15:961-973; 1995.
3. Beal, M. F., Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31:119-130; 1992.
4. Beal, M. F.; Broulillet, E.; Jenkins, B. G.; Ferrante, R. J.; Kowall, N. W.; Miller, J. M.; Storey, E.; Strivastava, R.; Rosen, B. R.; Hyman, B. T., Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13:4181-4182; 1993.
5. Borlongan, C. V.; Koutouzis, T. K.; Cahill, D. W.; Freeman, T. B.; Sanberg, P. R., Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in rats. Brain Res. Bull. 36:549-556; 1995.
6. Borlongan, C. V.; Koutouzis, T. K.; Cahill, D. W.; Freeman, T. B.; Sanberg, P. R., Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease. Brain Res. 697:254-257; 1995.
7. Bossi, S. R.; Simpson, J. R.; Isacson, O., Age dependence of striatal neuronal death caused by mitochondrial dysfunction. Neuroreport. 4:73-76; 1993.
8. Brouillet, E.; Hantraye, P.; Dolan, R.; Leroy-Willig, A.; Bottlaender, M.; Isacson, O.; Maziere, M.; Ferrante, R. J.; Beal, M. F., Soc. Neurosci. Abstr. 19 1993:409;.
9. Brouillet, E.; Jenkins, B. G.; Hyman, B. T.; Ferrante, R. J.; Kowall, N. W.; Strivastava, R.; Roy, D. S.; Rosen, B. R.; Beal, M. F., Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J. Neurochem. 60:356-359; 1993.
10. Brouillet, E.; Jenkins, B. G.; Hyman, B. T.; Ferrante, R. J.; Kowall, N. W.; Strivastava, R.; Roy, D. S.; Rosen, B. R.; Beal, M. F., Systemic or local administration of azide produces striatal lesions by a energy impairment-induced excitotoxic mechanism. Exp. Neurol. 129:175-182; 1994.
11. Bruyn, G. W., Huntington's chorea, historical, clinical and laboratory synopsis. Handbook Clin. Neurol. 6:298-378; 1968.
12. Cox, J. A.; Lysko, P. G.; Henneberry, R. C., Excitatory amino acid neurotoxicity at the N-methyl-D-aspartate receptor in cultured neurons: role of the voltage-dependent magnesium block. Brain Res. 499:267-272; 1989.
13. Filloux, F.; Wagster, M. V.; Folstein, S.; Price, D. L.; Hedreen, J. C.; Dawson, T. M.; Wamsley, J. K., Nigral dopamine type-1 are reduced in Huntington's disease: a postmortem autoradiographic study using the [3H] SCH23390 and correlation with [3H] forskolin binding. Exp. Neurol. 110:219-227; 1990.
14. Gould, D. H.; Gustine, D. L., Basal ganglia degeneration, myelin alterations, and enzyme inhibition in mice induced by the plant toxin 3-nitropropionic acid. Neuropathol. Appl. Neurobiol. 8:377-393; 1982.
15. Gusella, J. F.; Wexler, N. S.; Conneally, P. M.; Naylor, S. L.; Anderson, M. A.; Tanzi, R. E.; Watkins, P. C.; Ottina, K.; Wallace, M. R.; Sakaguchi, A. Y.; Young, Shoulson I.; Bonilla, E.; Martin, J. B., A polymorphic marker genetically linked to Huntington's disease. Nature 306:234-238; 1983.
16. Hamilton, B. F.; Gould, D. H., Nature and distribution of brain lesions in rats intoxicated with 3-nitropropionic acid: a type of hypoxic (energy deficient) brain damage. Acta Neuropathol. 72:286-297; 1987.
17. Hantraye, P.; Riche, D.; Maziere, M.; Isacson, O., A primate model of Huntington's disease: behavioural and anatomical studies of unilateral excitotoxic lesions of the caudate-putaman in the baboon. Exp. Neurol. 108:91-104; 1990.
18. Isacson, O.; Brundin, P.; Gage, F. H.; Bjorkland, A., Neural grafting in the rat model of Huntington's disease: progressive neuro-chemical changes after neostriatal ibotenate lesions and tissue grafting. Neurosci. 16:799-817; 1985.
19. Koroshetz, W. J.; Jenkins, B. G.; Beal, M. F.; Rosen, B. R., Localized proton-NMR spectroscopy in patients with Huntinton's disease (HD) demonstrates abnormal lactate levels in occipital cortex: evidence for compromised metabolism in HD. Neurology 42:319; 1992.
20. Koutouzis, T. K.; Borlongan, C. V.; Cahill, D. W.; Freeman, T. B.; Sanberg, P. R., Intrastriatal 3-nitropropionic acid: a behavioral assessment. Neuroreport. 5:2241-2245; 1994.
21. Koutouzis, T. K.; Borlongan, C. V.; Scorcia, T.; Creese, I.: Cahill, D. W.; Freeman, T. B.; Sanberg, P. R., Systemic 3-nitropropionic acid: long effects on locomotor behavior. Brain Res. Rev. 64:242-244; 1994.
22. Koutouzis, T. K.; Emerich, D.; Borlongan, C. V.; Freeman, T. B.; Cahill, D. W.; Sanberg, P. R., Cell transplantation for central nervous system disorders. CRC Crit. Rev. Neurobiol. 3:25-162; 1994.
23. Ludolph, A. C.; He, F.; Spencer, P. F.; Hammerstad, J.; Sabri, M., 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci. 18:492-498; 1991.
24. Martin, J. B.; Gusella, J. F., Huntington's disease: pathenogenesis and management. N. Engl. J. Med. 315:1267-1276; 1986.
25. Mettler, F. A., Choreoathetosis and striopallidonigral necrosis due to sodium azide. Exp. Neurol. 34:291-308; 1972.
26. Nishino, H.; Shimano, Y.; Kumazaki, M.; Sakurai, T., Chronically administered 3-nitropropionic acid induces striatal lesions attributed to dysfunction of the blood-brain barrier. Neurosci. Lett. 186:161-164; 1995.
27. Novelli, A.; Reilly, L. A.; Lysko, P. G.; Henneberry, R. C., Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energies are reduced. Brain Res. 451:205-212; 1988.
28. Sanberg, P. R.; Coyle, J. T., Scientific approaches to Huntington's disease. CRC Crit. Rev. Clin. Neurobiol. 1:1-44; 1984.
29. Shimano, Y.; Kumazaki, M.; Sakurai, T.; Hida, H.; Fujimoto, I.; Fukuda, A.; Nishino, H., Chronically administered 3-nitropropionic acid produces selective lesions in the striatum and reduces muscle tonus. Obesity Res. 3:779-784; 1995.
30. Shoulson, I. Huntington's Disease. In: Asbury, A.; McKhann, G. M.; McDonald, I., eds. The disease of the nervous system. Philadelphia: Ardmore Medical Books (W. B. Saunders); 1986:1258-1267.;
31. Stober, T.; Wussow, W.; Schimrigk, K., Bicaudate diameter - the most specific and simplified CT parameter in the diagnosis of Huntington's disease. Neuroradiol. 26:25-28; 1984.
32. The Huntington's Collaborative Group, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 72:971-983; 1993.
33. Zorumski, C. F.; Olney, J. W., Excitotoxic neuronal damage and neuropsychiatric disorders. J. Pharm. Ther. 59:145-162; 1993.